Exicure, Inc. (Nasdaq: XCUR, “Exicure”, “the Company”), has announced the signing of a Memorandum of Understanding (MOU) with ...

“Of the 927 studies identified, 14 randomized controlled trials were included. Thirteen of 14 studies (79%) observed a ...

To maximize its cash runway while the Board conducts its review of strategic alternatives, Viracta has elected to close its ongoing pivotal Phase 2 clinical trial of Nana-val in relapsed/refractory ...

Find out how atogepant, a new migraine medication, offers rapid relief and promotes prevention of migraine attacks. Learn about its benefits and mechanism of action.

While a stuffy nose is a common side effect of oral ED medications, switching from Cialis to shorter-lasting options like ...

Arvinas focuses on protein degradation, with its lead candidate, ARV-471, in Phase 3 trials for breast cancer. Read why we ...

Tinnitus affects up to 43% of people depending on definitions and populations studied. This phantom perception of sound can ...

Anavex Life Sciences remains one of the few non-amyloid Alzheimer's drug developers. Find out why I rate AVXL stock as a Hold ...

The most-read articles addressing mental health in 2024 spanned therapeutic advancements, research discoveries, and insight ...

Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to ...

The director of solid tumor therapy at Stanford Medicine describes how cellular therapies are transforming cancer care.

In a year of pivotal gastroenterology research, these 10 articles were in a class of their own, according to Dr David Johnson ...